Chemistry:Metaxalone

From HandWiki
Short description: Muscle relaxant
Metaxalone
Metaxalone.svg
Clinical data
Trade namesSkelaxin
AHFS/Drugs.comMonograph
MedlinePlusa682010
License data
Pregnancy
category
  • US: N (Not classified yet)
Routes of
administration
By mouth
ATC code
  • None
Legal status
Legal status
Pharmacokinetic data
BioavailabilityUnknown
MetabolismLiver
Elimination half-life9.2 ± 4.8 hours
ExcretionKidney
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC12H15NO3
Molar mass221.256 g·mol−1
3D model (JSmol)
  (verify)

Metaxalone, sold under the brand name Skelaxin, is a muscle relaxant medication used to relax muscles and relieve pain caused by strains, sprains, and other musculoskeletal conditions.[1] Its exact mechanism of action is not known, but it may be due to general central nervous system depression.[1] It is a moderately strong muscle relaxant, with relatively low incidence of side effects.[citation needed]

Common side effects include nausea, vomiting, drowsiness, and central nervous system (CNS) side effects, such as dizziness, headache, and irritability.[1]

The metabolism of metaxalone involves enzymes CYP1A2 and CYP2C19 in the cytochrome P450 system. Because many medications are metabolized by enzymes in this system, precaution must be taken when administering it with other medications involving the P450 system to avoid interactions.[2]

Because of the potential for side effects, this drug is considered high risk in the elderly.

Pharmacokinetics

Metaxalone exhibits increased bioavailability when taken with food.[3] Specifically, in one study, compared to fasted conditions, the presence of food at the time of drug administration increased Cmax by 77.5%, AUC0-t by 23.5%, and AUC0-∞ by 15.4%.[4] Metaxalone is a substrate of CYP1A2 and CYP2C19, an inhibitor of CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A, and an inducer of CYP1A2 and CYP3A4.[2]

Assay

A literature survey reveals very few methods are reported for the determination of metaxalone to date. Nirogi et al.[4] reported a liquid chromatographic method coupled to tandem mass spectrometry for the quantification of metaxalone in human plasma. A stability-indicating HPLC method was introduced by P.K. Sahu et al.[5] Metaxalone has been used as an internal standard for few analytical methods.[6][7]

References

  1. 1.0 1.1 1.2 1.3 "Skelaxin- metaxalone tablet". DailyMed. U.S. National Library of Medicine. 27 April 2018. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7a4163f2-c553-4d14-7e98-d14c5c7f772a. 
  2. 2.0 2.1 Du J, Roberts RH, "Metaxalone products, method of manufacture, and method of use", US patent 7378434, issued 27 May 2008, assigned to Takeda Pharmaceuticals USA Inc.
  3. "Skelaxin Package Insert". King Pharmaceuticals, Inc.. http://www.kingpharm.com/products/product_document.cfm?brand_name=Skelaxin&product_specific_name=&document_type_code=PI. 
  4. 4.0 4.1 "Quantification of metaxalone in human plasma by liquid chromatography coupled to tandem mass spectrometry". Journal of Analytical Toxicology 30 (4): 245–251. May 2006. doi:10.1093/jat/30.4.245. PMID 16803662. 
  5. "Development and Validation of Stability Indicating RP-HPLC Method for the Determination of Metaxalone in Bulk and its Pharmaceutical Formulations". e-Journal of Chemistry 8 (s1): S439–S447. 2011. doi:10.1155/2011/645710. 
  6. "High throughput LC-MS/MS method for simultaneous quantification of lamivudine, stavudine and nevirapine in human plasma". Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences 853 (1–2): 320–332. June 2007. doi:10.1016/j.jchromb.2007.03.047. PMID 17481969. 
  7. "HPLC-ESI-MS/MS validated method for simultaneous quantification of zopiclone and its metabolites, N-desmethyl zopiclone and zopiclone-N-oxide in human plasma". Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences 864 (1–2): 137–148. March 2008. doi:10.1016/j.jchromb.2008.02.004. PMID 18313371. 

External links